| 摘要 |
This disclosure relates biomarkers of cancer, e.g. prostate cancer. The biomarkers may be altered expression of nucleic acids, mutations, or proteins encoded therefrom. In certain embodiments, the disclosure relates to methods for diagnosing pro-state cancer, methods of distinguishing between less aggressive and high aggressive prostate cancer, methods of determining predisposition to recurrence of prostate cancer, methods of monitoring progression/regression of prostate cancer, methods of assessing efficacy of compositions for treating prostate cancer, and methods of screening compositions for activity in modulating biomarkers of prostate cancer. |
